Abstract
The peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor family of ligand-activated transcription factors. This study was designed to evaluate ligand activation of PPARgamma in human breast cancer cells. DNA binding by endogenous PPARgamma in gel shift assays and activation of PPARgamma by prostanoid and thiazolidinedione ligands in reporter gene assays differed between the cell lines. The PPARgamma ligands elicited an anti-proliferative effect in MTT proliferation assays. Our data point to a variable, cell-specific response to different gamma-ligands, which holds significance for further studies on the role of PPARgamma in mediating breast cancer growth and progression.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Breast Neoplasms
-
Cell Division / drug effects
-
DNA-Binding Proteins / metabolism
-
Female
-
Genes, Reporter
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Prostaglandins / pharmacology*
-
Receptors, Cytoplasmic and Nuclear / genetics*
-
Receptors, Cytoplasmic and Nuclear / metabolism*
-
Receptors, Retinoic Acid / genetics
-
Recombinant Proteins / metabolism
-
Retinoid X Receptors
-
Thiazoles / pharmacology*
-
Thiazolidinediones*
-
Transcription Factors / genetics*
-
Transcription Factors / metabolism*
-
Transcriptional Activation
-
Tumor Cells, Cultured
Substances
-
DNA-Binding Proteins
-
Hypoglycemic Agents
-
Prostaglandins
-
Receptors, Cytoplasmic and Nuclear
-
Receptors, Retinoic Acid
-
Recombinant Proteins
-
Retinoid X Receptors
-
Thiazoles
-
Thiazolidinediones
-
Transcription Factors
-
ciglitazone